TD Asset Management Inc Has $895,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Key Points

• TD Asset Management Inc reduced its stake in LENZ Therapeutics by 66.2%, now holding 34,828 shares valued at approximately $895,000 as of their latest SEC filing.
• LENZ Therapeutics' stock has a market capitalization of $836.55 million and has experienced a low of $16.53 and a high of $38.93 over the past twelve months.
• Analysts are optimistic about LENZ, with five giving it a "buy" rating and a consensus price target of $49.60 after several upgrades from notable firms.

TD Asset Management Inc cut its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 66.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,828 shares of the company's stock after selling 68,172 shares during the period. TD Asset Management Inc owned about 0.13% of LENZ Therapeutics worth $895,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of LENZ. KLP Kapitalforvaltning AS acquired a new stake in shares of LENZ Therapeutics in the 4th quarter valued at about $46,000. Tower Research Capital LLC TRC grew its stake in shares of LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after buying an additional 1,151 shares during the period. Virtus ETF Advisers LLC bought a new position in LENZ Therapeutics in the 4th quarter valued at about $67,000. GAMMA Investing LLC lifted its position in LENZ Therapeutics by 5,254.1% in the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after acquiring an additional 5,727 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new position in LENZ Therapeutics in the 4th quarter valued at about $215,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Stock Down 2.1%

LENZ Therapeutics stock opened at $29.33 on Tuesday. The company has a market capitalization of $836.55 million, a PE ratio of -15.44 and a beta of 0.42. The firm has a fifty day simple moving average of $31.05 and a two-hundred day simple moving average of $27.06. LENZ Therapeutics, Inc. has a twelve month low of $16.53 and a twelve month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million during the quarter, compared to analysts' expectations of $5.00 million. As a group, equities analysts expect that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler assumed coverage on shares of LENZ Therapeutics in a research report on Monday, April 14th. They issued an "overweight" rating and a $51.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price target (up previously from $38.00) on shares of LENZ Therapeutics in a research report on Monday, July 28th. Citigroup raised their price target on shares of LENZ Therapeutics from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Raymond James Financial increased their price objective on shares of LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $49.60.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.